To date there has been poor translation of immunotherapies from rodent models to treatment
of progressive multiple sclerosis (MS). In the robust, relapsing Biozzi ABH mouse model of
MS, using a combination of a transient deletion of T cells followed by intravenous (iv) myelin
antigen administration, established relapsing disease in EAE can be effectively silenced.
However, when treatment was initiated in late stage chronic-relapsing disease, despite
inhibition of further relapses, mice demonstrated evidence of disease progression shown by …